Toro PMJ, Parra PDR, Pacheco MNV, Galarza AGA. Enfermedad de Alzheimer. Recimundo. 2022;6:68–76.
Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzh Dement. 2023;19:658–70.
Woźniak K, Gardian-Baj M, Jung M, Hedesz P, Jung M, Żuk-Łapan A, et al. Alzheimer’s disease-a comprehensive review. J Educ Health Sport. 2024;56:195–209.
Grossberg G, Urganus A, Schein J, Bungay R, Cloutier M, Gauthier-Loiselle M, et al. A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia. J Med Econ. 2023;27:99–108.
Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizel LP, Bennett DA. The natural history of cognitive decline in Alzheimer’s disease. Psychol Aging. 2012;27:1008–17.
Article PubMed PubMed Central Google Scholar
Woodward MC. Drug treatment of Alzheimer’s disease: what has changed in 30 years? J Pharm Pract Res. 2024;53:314–19.
Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018;141:1917–1933.
Article PubMed PubMed Central Google Scholar
Hua KY, Zhao WJ. Current study on diagnosis and treatment of Alzheimer’s disease by targeting amyloid b-protein. Folia Neuropathol. 2022;61:8–15.
Iliyasu MO, Musa SA, Oladele SB, Iliya AI. Amyloid-beta aggregation implicates multiple pathways in Alzheimer’s disease: Understanding the mechanisms. Front. Neurosci. 2023;17:1081938.
Article PubMed PubMed Central Google Scholar
Twarowski B, Herbet M. Inflammatory Processes in Alzheimer’s Disease-Pathomechanism, Diagnosis and Treatment: A Review. Int J Mol Sci. 2023;24:6518.
Article CAS PubMed PubMed Central Google Scholar
Abdelazim AM, Abomughaid MM. Oxidative stress: an overview of past research and future insights. All Life. 2024;17:2316092.
Tian S, Huang Z, Meng Q, Liu Z. Multi-target drug design of anti-Alzheimer’s disease based on tacrine. Mini-Rev Med Chem. 2021;21:2039–64.
Article CAS PubMed Google Scholar
Kou X, Shi X, Pang Z, Yang A, Shen R, Zhao L. A review on the natural components applied as lead compounds for potential multi-target anti-AD theranostic agents. Curr Med Chem. 2023;30:4586–604.
Article CAS PubMed Google Scholar
Siemers E. Drug development in AD: point of view from the industry. JPAD-J Prev Alzheim. 2015;2:216–18.
Maniam S. Screening techniques for drug discovery in Alzheimer’s disease. ACS Omega. 2024;9:6059–73.
Article CAS PubMed PubMed Central Google Scholar
Pravin N, Jozwiak K. Effects of linkers and substitutions on multitarget directed ligands for Alzheimer’s diseases: Emerging paradigms and strategies. Int J Mol Sci. 2022;23:6085.
Article CAS PubMed PubMed Central Google Scholar
Kasus-Jacobi A, Washburn JL, Laurence RB, Pereira HA. Selecting multitarget peptides for Alzheimer’s disease. Biomolecules. 2022;12:1386.
Article CAS PubMed PubMed Central Google Scholar
Carreiras MC, Mendes E, Perry MJ, Francisco AP, Marco-Contelles J. The multifactorial nature of Alzheimer’s disease for developing potential therapeutics. Curr Top Med Chem. 2013;13:1745–70.
Article CAS PubMed Google Scholar
Rosini M, Simoni E, Caporaso R, Minarini A. Multitarget strategies in Alzheimer’s disease: Benefits and challenges on the road to therapeutics. Future Med Chem. 2016;8:697–711.
Article CAS PubMed Google Scholar
Atali S, Dorandish S, Devos J, Williams A, Price D, Taylor J, et al. Interaction of amyloid beta with humanin and acetylcholinesterase is modulated by ATP. FEBS Open Bio. 2020;10:2805–23.
Article CAS PubMed PubMed Central Google Scholar
Elsbaey M, Igarashi Y, Ibrahim MAA, Elattar E. Click-designed vanilloid-triazole conjugates as dual inhibitors of AChE and Aβ aggregation. RSC Adv. 2023;13:2871–83.
Article CAS PubMed PubMed Central Google Scholar
Kulshreshtha A, Piplani P. Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease. Neurol Sci. 2016;37:1403–35.
Anand A, Patience AA, Sharma N, Khurana N. The present and future of pharmacotherapy of Alzheimer’s disease: A comprehensive review. Eur J Pharmacol. 2017;815:364–75.
Article CAS PubMed Google Scholar
Benek O, Korabecny J, Soukup O. A perspective on multi-target drugs for Alzheimer’s disease. Trends Pharmacol Sci. 2020;41:434–45.
Article CAS PubMed Google Scholar
Oliveira C, Cagide F, Teixeira J, Amorim R, Sequeira L, Mesiti F, et al. Hydroxybenzoic acid derivatives as dual-target ligands: Mitochondriotropic antioxidants and cholinesterase inhibitors. Front Chem. 2018;6:126.
Article PubMed PubMed Central Google Scholar
Zhang C, Wang L, Xu Y, Huang Y, Huang J, Zhu J, et al. Discovery of novel dual RAGE/SERT inhibitors for the potential treatment of the comorbidity of Alzheimer’s disease and depression. Eur J Med Chem. 2022;236:114347.
Article CAS PubMed Google Scholar
Mao F, Wang H, Ni W, Zheng X, Wang M, Bao K, et al. Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer’s disease. ACS Chem Neurosci. 2017;9:328–45.
Dai R, Sun Y, Su R, Gao H. Anti-Alzheimer’s disease potential of traditional chinese medicinal herbs as inhibitors of BACE1 and AChE enzymes. Biomed Pharmacother. 2022;154:113576.
Article CAS PubMed Google Scholar
Karaca, Osmaniye D, Sağlık BN, Levent S, Ilgın S, Özkay Y, et al. Synthesis of novel benzothiazole derivatives and investigation of their enzyme inhibitory effects against Alzheimer’s disease. RSC Adv. 2022;12:23626–36.
Article CAS PubMed PubMed Central Google Scholar
Yao H, Uras G, Zhang P, Xu S, Yin Y, Liu J, et al. Discovery of novel tacrine–pyrimidone hybrids as potent dual AChE/GSK-3 inhibitors for the treatment of Alzheimer’s disease. J Med Chem. 2021;64:7483–506.
Article CAS PubMed Google Scholar
Soliman AM, Ghorab WM, Lotfy DM, Karam HM, Ghorab MM, Ramadan LA. Novel iodoquinazolinones bearing sulfonamide moiety as potential antioxidants and neuroprotectors. Sci Rep-UK. 2023;13:15546.
Skrzypek A, Matysiak J, Karpinska M, Czarnecka K, Krecisz P, Stary D, et al. Biological evaluation and molecular docking of novel 1,3,4-thiadiazole-resorcinol conjugates as multifunctional cholinesterases inhibitors. Bioorg Chem. 2021;107:104617.
Article CAS PubMed Google Scholar
Gul Q, Karim N, Shoaib M, Zahoor M, Rahman MU, Bilal H, et al. Vanillin derivatives as antiamnesic agents in scopolamine-in
留言 (0)